Galapagos NV
Research Galapagos NV (GXE) on Bullrun: market cap EUR 1.62B, P/E 3.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGXE
- ExchangeF
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.62B
- P/E3.3
- Financial periodFY2025
- RevenueEUR 1.11B
- Revenue growth303.5%
- Net incomeEUR 320.88M
- Free cash flow-EUR 271.16M
- Gross margin97.3%
Valuation Snapshot
latest market cap is EUR 1.62B; P/E is 3.3.
Peer valuation comparison
Latest P/E is 3.32x versus a Healthcare sector median of 24.46x (86.4% below).
Latest P/E is 3.32x versus a Belgium median of 13.16x (74.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 1.11B | EUR 320.88M | -EUR 271.16M | 97.3% | 4.87 | EUR 87.87M | n/a | EUR 3.24B |
| FY2024 | EUR 275.65M | EUR 74.08M | -EUR 336.75M | 87.4% | 1.12 | EUR 64.24M | n/a | EUR 2.90B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-06-16 | EUR 1.62B | 3.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Galapagos NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Galapagos NV's market cap?
Galapagos NV's market capitalization is EUR 1.62B.
What is Galapagos NV's P/E ratio?
Galapagos NV's price-to-earnings (P/E) ratio is 3.3.
What does Galapagos NV do?
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.